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A B S T R A C T
Background: Many depressed patients are not able to achieve or sustain symptom remission despite serial
treatment trials – often termed “treatment resistant depression”. A broader, perhaps more empathic concept of
“difficult-to-treat depression” (DTD) was considered.
Methods: A consensus group discussed the definition, clinical recognition, assessment and management im-
plications of the DTD heuristic.
Results: The group proposed that DTD be defined as “depression that continues to cause significant burden
despite usual treatment efforts”. All depression management should include a thorough initial assessment. When
DTD is recognized, a regular reassessment that employs a multi-dimensional framework to identify addressable
barriers to successful treatment (including patient-, illness- and treatment-related factors) is advised, along with
specific recommendations for addressing these factors. The emphasis of treatment, in the first instance, shifts
from a goal of remission to optimal symptom control, daily psychosocial functional and quality of life, based on a
patient-centred approach with shared decision-making to enhance the timely consideration of all treatment
options (including pharmacotherapy, psychotherapy, neurostimulation, etc.) to optimize outcomes when sus-
tained remission is elusive.
Limitations: The recommended definition and management of DTD is based largely on expert consensus. While
DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical
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populations for regulatory trial purposes, though DTD could define populations for service provision or phase 4
trials.
Conclusions: DTD provides a clinically useful conceptualization that implies a search for and remediation of
specific patient-, illness- and treatment obstacles to optimizing outcomes of relevance to patients.
1. Introduction
Depression is associated with a high burden of disease (GBD 2015
DALYs and HALE Collaborators 2016). Fortunately, there are many
treatments, including pharmacological, psychological and neuro-
stimulatory options that are associated with remission of symptoms and
full restoration of psychosocial function (Malhi and Mann, 2018). If
there is a lack of response to, or tolerability of, initial treatment, al-
ternatives can be trialled. In other instances, acute responses may be
obtained but subsequent relapses occur even on treatment. Un-
fortunately, a significant proportion of patients do not achieve sus-
tained remission, despite serial treatments (Rush et al., 2006).
One way of conceptualizing the issue of non-response is as ‘treat-
ment-resistant depression’ (TRD). TRD is often thought of as describing
patients beyond a certain threshold in a course of serial treatment trials.
While there is no universally accepted definition, it is often defined as
failure to respond to at least two adequate courses of antidepressants
(Brown et al., 2019). There are, however, many issues with such defi-
nitions (Rush et al., 2019). For example, it is unclear how psy-
chotherapeutic and neurostimulatory treatments should be “counted”,
or how to account for differential efficacy among treatments, when
assessing the degree of TRD (Brown et al., 2019; McAllister-
Williams et al., 2018). There is also a semantic issue with the termi-
nology: who or what is “resistant” – the patient or the illness? The
phrase also implies a medical model (Rush et al., 2019) and can lead to
social and environmental factors that might be barriers to recovery not
being considered.
Inherent in all definitions of TRD is the concept that the manage-
ment of depression involves serial acute treatment trials (Rush et al.,
2019). In some health care settings it is clear that many patients receive
suboptimal treatment, for example being continued on antidepressants
to which they are not responding for long periods, without considera-
tion of alternative or additional pharmacological options (Wiles et al.,
2018). In such situations considering further serial options following a
treatment algorithm may be extremely valuable (Kraus et al., 2019).
Several novel psychotherapeutic, pharmacological and neuro-
stimulatory options have recently joined the treatment arma-
mentarium, with more in development. This is a boon, but forces the
question of when and for whom to choose these newer, often more
expensive and/or invasive treatments (Conway et al., 2017; McAllister-
Williams et al., 2018; Rush et al., 2019). Since some patients do not
response acutely, and others do not sustain their responses despite
multiple treatments (Judd et al., 1998; Rush et al., 2006), how long
should clinicians go on recommending further acute treatment trials? If
all available options and combinations are tried this would take more
than a lifetime. Clearly, we should neither undertreat nor overtreat.
When is it parsimonious to reconsider the differential diagnosis and
case formulation, and to contemplate a different approach – perhaps to
address psychosocial stressors or to develop ways to cope with or adjust
to some of their symptoms?
Such an approach to the management of patients with depression
and sub-optimal outcomes is encapsulated in the concept of “difficult to
treat depression” (DTD) (Rush et al., 2019). “DTD” has advantages over
“TRD” in that it is recognizes the shared responsibility between clin-
ician and patient to manage the illness and the need to take a long-term
and holistic perspective that is individualized to the patient (Rush et al.,
2019). Further, DTD conceptualizes the management of depression
somewhat differently to that of a TRD model. DTD views depression as
treatable (“difficult” but not “impossible”) while recognizing that it is
associated with challenges that may require special consideration be-
yond the standard treatment pathway. In such circumstances the focus
is around optimization of symptom control, maximizing function and
minimizing treatment burden where remission cannot be obtained
(Rush et al., 2019). Such an approach is analogous to the management
of chronic somatic illness such as rheumatoid arthritis (Luqmani et al.,
2009) or the recovery model as applied, for example, to schizophrenia
(Warner, 2009).
The DTD model has previously been described, including identi-
fying key questions for future research (Rush et al., 2019). This paper
draws on this DTD model to provide specific clinical guidance regarding
the assessment and management of patients with suspected or actual
DTD. Ideally guidelines are based on evidence, for example from ran-
domized controlled trials. However, there is little evidence for selecting
one treatment over another for depressions that have failed to respond
to several prior treatments. Patients can have an almost infinite number
of possible past treatment histories when one considers the order of
treatments, their dose and duration, other treatments used in combi-
nation, and the degree of response and level of tolerability. When this is
combined with the various predisposing, precipitating and perpetuating
factors related to their depression and its non-response, it is apparent
that a nomothetic perspective may not be possible, and an idiographic
approach may be more appropriate. This paper therefore seeks to
provide clinical guidance for the assessment and management of DTD
based on evidence-based principles and expert consensus.
2. Methods
An international group of psychiatrists with expertise in affective
disorders, comprising 15 individuals from across Europe, US, Canada
and Australia convened to discuss issues relating to DTD, in the context
of major depressive disorder (MDD). Objectives were agreed, and a
selection of relevant literature on TRD and DTD identified (Brown et al.,
2019; Conway et al., 2017; Kraus et al., 2019; Malhi et al., 2019;
McAllister-Williams et al., 2018; Rush et al., 2019; Rush and
Thase, 2018). A one-day consensus meeting was held in London, UK, on
1st April 2019 (attended by RHMW, CA, PB, KD, PG, AJ, SK, JCS, EV,
AP and AJR). This meeting was specifically tasked with producing a
consensus paper addressing: the terminology to define DTD; identifi-
cation and assessment of patients with DTD; and treatment options for
DTD. Treatment options were identified based on review of treatment
guidelines (British Association of Psychopharmacology [BAP]
[Cleare et al., 2015], Canadian Network for Mood and Anxiety Treat-
ments [CANMAT] [Kennedy et al., 2016; Milev et al., 2016;
Parikh et al., 2016], World Federation of Societies of Biological Psy-
chiatry [WFSBP] [Bauer et al., 2013]) to ascertain those with evidence
for efficacy in populations with a history of treatment failure, as well as
review of literature on newer treatment options that have become
available since publication of guidelines. A draft manuscript was
written and circulated amongst the authors and revised iteratively
based on comments received. Consensus was not possible on all issues,
but this final document reflects broad agreement on principles to which
all authors could subscribe.
3. Concensus
3.1. Terminology and definition of DTD
Depressive episodes may occur as part of major depressive or
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bipolar disorders or secondarily to other psychiatric/neurological ill-
ness such as schizophrenia, Parkinson's disease or dementia. This con-
sensus paper focuses on MDD, though many of the principles would
equally apply to bipolar disoder. However, the differentiation between
episodes of depression occurring in different contexts is an important
element in the assessment of DTD (see below).
The majority of the consensus group preferred the use of DTD ter-
minology over TRD. TRD was considered by many to lack empathy and
suggest a defeatist attitude to treatment, while DTD was perceived as a
more open concept that could foster a collaborative approach between
physician, patient and carers/family members to overcome difficulties/
challenges. Some concerns were expressed about the DTD terminology.
The DTD approach is in part based upon that taken with many chronic
somatic illnesses, and it was pointed out that “difficult-to-treat dia-
betes” or “difficult-to-treat rheumatoid arthritis” would probably be
unacceptable in other areas of medicine. It was also acknowledged that
“difficult” is a somewhat negative word, and that it could be asked who
or what is ‘difficult’ – the patient or the illness. However, it was agreed
that TRD was semantically not ideal and the move towards DTD was
generally felt to be a significant step in the right direction, emphasising
the critical role for the health care practitioner (the person who is
finding treatment difficult), and with increasing recognition in the
psychiatric community (Rush et al., 2019; Wilhelm, 2019). It was
agreed that a fundamental principle of the concept is to convey a po-
sitive message – that depression might be “difficult” to treat but not
impossible and that strategies to manage it exist, with a goal of im-
provement in the quality of life of people suffering with DTD.
The consensus group proposed a definition of DTD, or “suspected
DTD”, and described this as “depression that continues to cause significant
burden despite usual treatment efforts”. The continuing burden may be
due to difficulties in: achieving response or remission acutely, sus-
taining the acute phase response or remission, returning to premorbid
levels of function and quality of life, lack of functional restoration de-
spite good symptomatic control, or unacceptable tolerability or non-
adherence or rejection of the treatment option. It is patient defined.
“Usual treatment efforts” will depend on the health care setting and
environment and relate to local treatment guidelines and practice. The
key to the definition is that in the circumstances in which the patient's
depression is being treated it is perceived as “difficult to treat”. The
treatment can be of any modality (e.g. psychotherapy, pharma-
cotherapy, neurostimulation) and the failure of this to reduce the
burden of illness might be due to non-response, intolerance, lack of
acceptance or contraindication of the treatment. DTD differs from
conventional descriptions of TRD that focus exclusively on acute
treatment phase symptomatic response (Rush et al., 2019). It is ac-
knowledged that the DTD ‘label’ will encompass a very heterogenous
group of individuals.
The consensus group discussed whether a minimum number of
treatment failures should be necessary for a patient to be considered to
have DTD. Some evidence suggests that response and remission rates to
third or fourth treatment steps are significantly lower than to first or
second line treatments (Gaynes et al., 2018; Rush et al., 2006), which
supports an argument for TRD being defined after failure to respond to
two treatments (Gaynes et al., 2018; Brown et al., 2019). As a result, it
was agreed that, while a strictly defined number of treatment failures
may not be helpful outside of the research or regulatory settings, sus-
pected DTD should normally be considered after at least two treatment
trials. However, some patients with a single treatment failure might be
considered to have DTD e.g., where comorbidities and concomitant
medications are contraindications for many standard treatment options.
What constitutes “significant burden” in the definition of DTD is
subjective and likely to vary between patients. It was generally agreed
that burden relates more to impairments in daily function, quality of
life, and/or symptoms rather than resting exclusively on depressive
symptomatology, though it was argued by some that symptoms are the
driver of the burden. Adverse effects of treatment also contribute to the
overall burden experienced by the patient.
If depression continues to cause significant burden despite standard
first- and second-line treatment efforts, then it may be considered
“suspected DTD”. Simply adjusting, switching or augmenting the cur-
rent treatment may lead to a sustained full remission of symptoms with
restoration of function. As such, the depression may not be "difficult to
treat". At what point suspected DTD becomes DTD is a clinical decision,
based on a thorough assessment of the patient and illness character-
istics, and treatment history (see Section 3.2). Essentially a patient's
depression might be viewed as DTD if the depression continues to cause
significant burden despite adequate standard treatment trials and at-
tempts at addressing all easily tractable maintaining issues identified in
the assessment and/or there being ongoing less tractable factors helping
to maintain a sub-optimal outcome. Whether a clinician views the de-
pression as difficult to treat will depend on their own expertise and the
nature of the health care setting in which they are working. This may
include the responsiveness of the system and what constraints are
placed on the clinician (e.g., limited time for consultations or restric-
tions on access to treatments). If a clinician feels that a specific factor or
factors are leading to the depression being difficult to treat, then this
should be a precipitant to seeking advice from a colleague or referring
the patient to a more specialist centre if available. This may lead to an
adjusted assessment and an altered clinical decision as to whether the
patient is or is not suffering from DTD.
DTD and TRD are related, overlapping, concepts but with key dif-
ferences. Firstly, TRD is defined by a failure to respond to treatment,
while DTD is defined by lack of acute phase response/remission or not
sustaining the acute response/remission. Secondly, TRD is unidimen-
sional resting solely on depressive symptom outcomes. In addition to
symptoms, DTD considers psychosocial functioning and quality of life
from a patient perspective. Thirdly, the action implied by the TRD
concept is further acute treatment trials, while the consensus group
argues that the DTD concept calls for re-evaluation of the depression, a
search for treatable biomedical and psychosocial causes of poor out-
come, and consideration of a shift in treatment goals from remission to
optimal management. The proposed concept and definition of DTD is
intended for clinical practice (as described above) rather than research
or regulatory affairs, in large part because of its idiographic approach.
TRD, as conventionally defined, is likely to remain of relevance for drug
approval and commissioning of services since these necessarily require
a nomothetic approach.
Just as in TRD (Malhi et al., 2019), this broad umbrella definition of
DTD encompasses a large and heterogeneous group of patients, with
different characteristics, different treatment histories, and different le-
vels of ongoing burden. Identifying a depression that meets the broad
description of suspected DTD is a starting point for a thorough assess-
ment (see next section) to identify a treatment paradigm that will be
best place to remedy, or at least reduce, the multiple obstacles that
prevent full resolution of the symptomatic and dysfunctional state. It
was considered impractical to define clearly delineated subcategories of
DTD due to the large number of possible permutations of illness and
treatment history variables. Rather, it was agreed that it is more clini-
cally useful to consider specific aspects of DTD at an individual level for
patients meeting the broad description of DTD, i.e., taking an idio-
graphic approach.
Several numerical staging models have been proposed for TRD, and
these have some predictive utility (Fava, 2003; Fekadu et al., 2018;
Kraus et al., 2019; Ruhé et al., 2012). While the patient's treatment
history is an important prognostic indicator, other factors are also cri-
tical in the understanding and management of DTD. These multi-di-
mensional factors do not easily lend themselves to a simplistic quanti-
tative staging system. Consequently, the consensus group does not
propose staging or numerical scoring to indicate the “degree” of diffi-
culty of treatment for the depression an individual is suffering, at this
time. Further research is required to explore the optimal way of ob-
jectively assessing DTD. This may involve a combination of assessments
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of depressive symptoms, psychosocial function, quality of life, treat-
ment response and course of illness.
3.2. Assessment of DTD or suspected DTD
Diagnosis and (regular) assessment of patients with DTD or sus-
pected DTD is critical for the effective management of the depression
(Malhi et al., 2019).
The starting point for assessment is consideration of the differential
diagnosis of the presenting major depressive episode (MDE). Is the
episode occurring secondary to some organic pathology, for example
dementia or a cerebrovascular accident, or in the context of a non-af-
fective psychotic illness? In either case, the depression is very likely to
be difficult to treat and the management paradigm for DTD is appro-
priate alongside management of the primary pathology where possible.
In terms of affective disorders, an important differential diagnosis is
between MDD and bipolar disorder. There is evidence of higher rates of
undiagnosed bipolar disorder in treatment resistant versus non-resistant
depression (Perugi et al., 2019; Sharma et al., 2005). This may relate to
the observation that bipolar depression does not tend to respond to
standard antidepressant medications (McGirr et al., 2016;
Pacchiarotti et al., 2013; Sidor and MacQueen, 2012) and alternative
treatment strategies are required (Goodwin et al., 2016; Grunze et al.,
2018; Yatham et al., 2018).
In terms of diagnostic assessment, the presence of comorbid illness
or symptoms is of profound importance in terms of the distinction
between suspected and actual DTD. The rule of thumb is that all
comorbidities increase the risk of non-response to treatment. A core,
but not exhaustive, list of comorbidities to specifically assess for
include anxiety (Fava et al., 2008), substance misuse (Howland
et al., 2009), psychotic symptoms (Jääskeläinen et al., 2018) and
pain (DeVeaugh-Geiss et al., 2010). Assessment for dysthymia is also
important. The situation becomes complex when considering
“double depression” (the comorbidity of dysthymia and an MDE)
and differentiating between residual depressive symptoms following
treatment of an MDE versus a return from double depression to a
dysthymic state. The goal of full and sustained remission may be
more achievable in the former compared with the latter situation
(Rhebergen et al., 2009). Other diagnostic issues such as depression
secondary to general medical disorders or iatrogenic causes are
discussed further below.
Beyond issues of the primary diagnosis, the consensus group pro-
poses a three-dimensional model for the assessment of suspected DTD,
with dimensions of patient characteristics, illness characteristics and
treatment history. This model is based upon the evidence regarding
outcome and prognosis of patients with depression. Table 1 lists some
of the many potential factors to consider under each dimension, based
on a selective review of some key references exploring risk factors for
non-response to treatment. It is important to note that the various
factors in the model are not necessarily independent. One strength of
the proposed model is that it promotes thinking in terms of patient*-
disease*treatment interactions, providing a framework for considera-
tion of multiple factors that could impact treatment outcomes. This
contrasts with a treatment-focussed approach, as suggested by TRD
terminology, which can lead to continuing along the treatment pathway
without pausing to address other factors. Table 1 highlights many
factors that could be relevant to DTD overall, as heterogeneous patient
group. Only a few factors may be applicable to any particular patient. In
addition to factors shown in Table 1, the nature of health care delivery
and the degree of patient engagement with their treatment also impacts
the outcomes of patients with depression (Rush and Thase, 2018). This
is discussed further in Sections 3.3 and 3.4.
3.2.1. Patient characteristics
Numerous patient characteristics are associated with poorer treat-
ment outcomes (see Table 1). Characteristics with the greatest effect
include childhood trauma, stressful life events and marital status of
being divorced or separated. Some of these (e.g., childhood trauma and
family history of mood disorders) are not amenable to direct inter-
vention (though may be important foci for prevention of mental ill
health), but they may influence how a patient's depression may be
managed. For example, various psychotherapeutic options may be
considered when there is a history of past trauma, a history of suc-
cessful medical treatment of a family member may influence medica-
tion choice for the patient. Other factors may be more directly targe-
table by psychosocial interventions (such as social isolation and lack of
employment).
While there is surprisingly relatively little data regarding the role of
personality traits on treatment outcome and likelihood of non-response,
undoubtedly, they can play an important role in the risk of developing
depression and the likelihood of treatment response or relapse. For
example, optimistic, but not pessimistic, personality traits influence the
risk of becoming depressed while both influence outcome and like-
lihood of returning to work (Kronström et al., 2011). Dependency traits
may also affect help-seeking and outcome to treatment of depression
(Rost et al., 2019). Patients’ perspectives on their situations are of
paramount importance and may be a focus for self-management (see
Section 3.4.6).
3.2.2. Illness characteristics
Again, there are numerous illness characteristics that impact on the
ease and difficulty of managing depression and influence management
strategies (see Table 1). The characteristic associated with by far the
highest risk of a poor outcome compared with all others (patient, illness
or treatment) is the lack of full remission and presence of residual
symptoms after appropriate treatment. This highlights the importance
of striving for depressive symptom remission if at all possible. Other
than this, comorbidity of any nature is associated with a poorer out-
come, as discussed above. While some post-hoc analyses suggest that
patients with atypicality respond to monoamine oxidase inhibitors
(Pae et al., 2014), the importance of symptom profile to treatment
choice is contentious, with some data finding no clear relationship
symptom profile and response to different treatments (Arnow et al.,
2015; Rush et al., 2008). However, there is clear importance of iden-
tification of serious symptoms associated with risk (e.g. suicidality) or
the need for additional treatment (e.g. psychosis). Some comorbid
mental illnesses, such as obsessive-compulsive disorder, may influence
treatment choice (Hoehn-Saric et al., 2000). Similarly, comorbid phy-
sical illness, for example a recent myocardial infarction, may influence
treatment choice from a safety perspective (Glassman et al., 2002).
3.2.3. Treatment history
The adequacy of past treatment trials, whether psychological,
pharmacological or neurostimulatory in nature, should be assessed.
Treatment failures throughout the disease course (not just the current
episode) are relevant. The types of medication previously used may
inform subsequent treatment choices and inform the degree of difficulty
that might be expected. For example, has the patient just had multiple
trials of selective serotonin reuptake inhibitors (SSRIs) as opposed to a
variety of drugs with at least slightly different mechanisms of action?
The latter would suggest a greater degree of difficulty of treatment.
Failure to respond to particular treatments may be especially relevant
when considering degree of difficulty of treatment. For example, five-
year longitudinal data suggests that the outcome of patients who have
failed to respond to electroconvulsive therapy (ECT) is worse than those
that have (Aaronson et al., 2017). Whether the treatment failed to
generate an acute response or remission, or failed to sustain an acute
benefit, may inform the next treatment strategies. The consensus group
identified a change in brand of a drug as a possible reason why relapse
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can occur in patients with DTD. Given the importance of remission for
maximising functional outcomes and minimising risk of relapse, partial
but inadequate response should also be considered a treatment failure.
The place of pharmacogenetic testing and therapeutic blood level
monitoring is unclear in the work up of patients with DTD (Rush et al.,
2019). Medication plasma levels may be helpful in identifying non- or
partial-adherence and as pharmacogenetic evidence grows, this may
become increasingly relevant to consider (Hicks et al., 2019).
The proposed heuristic, like any other, has limitations. It does not
take into account other factors that may affect outcome, including the
patient's psychosocial environment and health care setting.
Psychotherapies that address interpersonal environmental factors that
contribute to DTD should be considered when such factors are deemed
important (which would be identified under the ‘patient’ or ‘treatment’
element of the model proposed above). The health care setting may well
affect outcome and needs to be addressed on a patient by patient basis,
considered under the ‘treatment’ section above.
A thorough assessment is essential to identify any aspect of a pa-
tient's depression that if properly addressed could make the depression
more manageable. For example, a patient's poor adherence, if identi-
fied, may benefit from psychoeducation or formal psychotherapy; a
patient with a substance use disorder could be referred to appropriate
services to manage that aspect of their illness; a patient in whom in-
vestigations reveal hypothyroidism can be treated with thyroxine.
These examples illustrate that straightforward interventions can facil-
itate management of depression that otherwise appeared quite chal-
lenging before these factors were identified and addressed. They
highlight the importance of identifying potentially modifiable factors,
underlying causes, and comorbidities. A summary of investigations
recommended as part of the thorough assessment of patients presenting
with apparent DTD in primary or specialist care settings is presented in
Table 2.
3.3. Goals and principles of the management of DTD
The group identified several goals of treatment and principles as to
how to manage DTD (Fig. 1).
The first goal is to ‘strive for optimal symptom control’. While the
concept of DTD encompasses the notion that it is not always possible to
achieve symptomatic remission (Rush et al., 2019), its potential im-
portance in reducing risk of relapse (Judd et al., 1998; Rush et al.,
2006) and optimizing psychosocial functioning (Fried and Nesse, 2014;
Kennedy and Paykel, 2004; Romera et al., 2010) means that identifying
a patient's depression as difficult to treat does not mean that such a goal
should be abandoned. Indeed, this should be the default goal of treat-
ment. However, in patients with DTD it is also important to consider the
burden of treatment that can come with increased doses of medication
and polypharmacy. This calls for optimization of symptom control ba-
lanced against burden of treatment. Even in patients suffering from a
chronic episode of depression, there is a degree of waxing and waning
of symptoms (Judd et al., 1998). As a result, the second goal is to take
steps to ‘reduce risks and impact of relapse’. Whatever the situation
with regards the level depressive symptomatology, the most important
consideration, and third goal, is ‘optimization of psychosocial func-
tioning’ and return to a “meaningful life” (Zimmerman et al., 2006).
The first principle in the management of DTD is identification of
treatment goals based upon ‘shared decision making’ with the patient.
This is a critical step in the broad principle of treatment ‘enhance
engagement and retention in services’ (Rush and Thase, 2018). What
is clear is that a higher concordance between physician and patient
expectations from treatment results in better outcomes
(Demyttenaere et al., 2015). In addition to the utilization of a broad
range of psychological, pharmacological and neurostimulatory treat-
ments, it is important to empower patients through ‘supporting self-
management strategies’, a key principle aimed at preparing patients,
and where appropriate their families or support systems, to effectively
manage DTD over the longer term.
A principle strongly endorsed by the consensus group was the im-
portance of measurement, which has important parallels with the
management of chronic somatic illnesses. Clinicians would not dream
of treating hypertension and not measuring it. There is evidence that
simply ‘implementing measurement-based care’ by measuring the
severity and different domains of patient's depression can significantly
improve outcomes (Guo et al., 2015).
An overarching principle in the model is having ‘integrated service
pathways’. There is evidence that, in some health care settings, pa-
tients with DTD ‘fall between the cracks’ between primary and sec-
ondary care (Wiles et al., 2018). This may in part relate to symptoms of
hopelessness that patients with DTD may experience, leading them to
not actively seek the care they need. Finally, it is essential that the
management of DTD includes ‘frequent re-assessment and con-
sideration of treatment direction’. Aside from standard clinical re-
views, from time to time it is important to review the comprehensive
assessment of the patient described above. Have any of the identified
factors resolved or become more problematic? Are there new factors to
consider? This then leads onto reviewing what direction treatment
might progress over the next period of time. Is there a case for one or
more acute treatment trials, for example with a newly available option
(in other words following a more traditional TRD model of treatment
(e.g. Kraus et al., 2019)? Alternatively, is there a case for considering a
longer-term treatment such as vagus nerve stimulation (VNS), or a
psychotherapeutic approach to address some underlying factor, along-
side current medication? The guiding principle here is avoiding both
under- and over-treatment.
Table 2
Investigations of patients with DTD: recommendations for primary and spe-
cialist care.
Primary care Specialist care (additionally to primary care)
Blood tests
-Complete blood count
-Thyroid function tests
(including TSH)
-Ferritin
-Vitamin B12
-HbA1c
-CRP
-Liver function tests
(including GGT)
-Menopausal markers (FSH,
LH) in women
-Testosterone in men
Vital signs
-Blood pressure
-Heart rate
-Weight/BMI
Symptom questionnaires/scales
-PHQ-9
-GAD-7
Cognitive tests
-MMSE (to exclude dementia)
Blood tests
-Magnesium, calcium
-Vitamin D
Hormonal status
-Further investigation of menopausal
markers
-Mood fluctuation around menstrual cycle
Cognitive tests
-DSST – provides a quick assessment of
multiple cognitive domains
-MoCA
Symptom questionnaires/scales e.g.
-MADRS, HDRS and/or IDS/QIDS (self-rated
or clinician)
-MDQ (to screen for bipolar disorder)
-AUDIT (to screen for alcohol misuse)
-SDS (to assess the key issue of psychosocial
function)
Objective sleep assessment (if indicated to
exclude a sleep disorder)
-Polysomnography/actigraphy
Neuroimaging
-CT/MRI/SPECT – e.g. to identify organicity
such as a dementia
AUDIT, Alcohol Use Disorders Identification Test; BMI, body mass index; CRP,
C-reactive protein; CT, computerized tomography; DSST, digit symbol sub-
stitution test; FSH, follicle stimulating hormone; GAD-7, generalized anxiety
disorder 7-item scale; GGT, gamma glutamyl transpeptidase; HbA1c, glycated
haemoglobin; HDRS, Hamilton Depression Rating Scale; IDS, Inventory of
Depressive Symptomatology; LH, luteinizing hormone; MADRS,
Montgomery–Åsberg Depression Rating Scale; MDQ, Mood Disorder
Questionnaire; MMSE, mini-mental state examination; MoCA, Montreal
Cognitive Assessment; MRI, magnetic resonance imaging; PHQ-9, patient health
questionnaire (9-items); QIDS, Quick Inventory of Depressive Symptomatology;
SPECT, single photon emission computed tomography; SDS, Sheehan Disability
Scale; TSH, thyroid stimulating hormone.
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3.4. Managing DTD: putting principles into practice
Fig. 2 provides an overview of practical approaches that can be
employed to help achieve the goals set out in Fig. 1 and put the key
principles in the management of DTD into practice.
3.4.1. Achieve optimal symptom control using measurement-based
treatment
It is not possible to provide a treatment algorithm, as there is no
standard treatment pathway given the considerable variability among
patients and their illness and treatment histories, all of which might
influence treatment choices alongside patient preference. Some barriers
to treatment may remain. For example, access to resources, local
treatment approval status or access to treatment centres may limit
treatment options.
Patients suffering from chronic DTD that has not responded to
multiple treatments frequently feel hopeless, which can negatively
impact their engagement with services and adherence with
management strategies. This presents a significant challenge to clin-
icians. The reader is directed to Rush and Thase (2018) who present a
set of comprehensive strategies to enhance engagement and adherence
using a patient-centred approach. An element of this is the use of
‘shared decision making’ around treatment selection and implementa-
tion. This is advocated to take account of patients’ preferences and
promote a positive attitude towards their treatment. Engaging suppor-
tive partners (e.g., spouse, parent, etc.) in treatment decisions is de-
sirable too, where possible. Managing patients’ expectations is also
important, particularly in DTD where restoring function to the best
level possible for the individual patient is often a more realistic goal
than a full return to pre-morbid functionality or complete remission.
Understanding that some level of ‘scarring’ is likely to remain (just as it
would from a physical wound) should help combat pessimism about
residual deficits and allow a shift in focus to positive and meaningful
improvements in functioning and quality of life.
It is always important to consider a goal of symptomatic remission
though this is not always practical, at least in the first instance. In
Fig. 1. Goals and principles in the management of DTD.
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Fig. 2. Managing DTD: Putting principles into practice.
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Fig. 2. (continued)
R.H. McAllister-Williams, et al. Journal of Affective Disorders 267 (2020) 264–282
272
considering recommendations for managing DTD, the group have used
the term ‘controlling illness’ drawing from the parallel of managing
chronic somatic illness. To achieve this, when managing a patient's DTD
there may be different phases of treatment. Early on, for example after
just two failed antidepressant medication trials, it is likely that a more
traditional approach of a series of acute treatment trials of different
medications, neurostimulatory techniques, psychotherapies and treat-
ment combinations may be very appropriate. The conceptualization of
DTD (Rush et al., 2019) suggests that at some point that a broader
perspective, ideally guided by the assessment of the patient and their
depression, and the context of the care delivery system, be considered
wherein the goal of treatment may be revised from symptom remission
to optimal symptom control. This revised treatment focus should not
preclude regular reconsideration of further acute treatment trials in the
future.
3.4.1.1 Treatment options. An expanding armamentarium of treatment
options is available to clinicians. Importantly these include biological
options with mechanisms of action going beyond medications with
direct action on monoamine transmission (e.g., esketamine [Daly et al.,
2019; Popova et al., 2019], transcranial magnetic stimulation
[Chen et al., 2017], VNS [Aaronson et al., 2017] and deep brain
stimulation [Kisely et al., 2018]). How treatments might be sequenced
is well described in the review by Kraus et al. (2019).
A key question is when the clinician should depart from more
conventional treatments to ones that are more expensive, more in-
vasive, associated with a higher side effect burden and/or supported by
less robust data. This is discussed in the review by McAllister-
Williams et al. (2018), which concluded that ‘non-standard’ interven-
tions are often not considered until later in the treatment pathway than
may be appropriate. A full range of treatment options, beyond phar-
macotherapy, should be considered. If significant psychosocial stressors
are identified it may be appropriate to consider social interventions or
psychotherapy to help the patient cope with those stressors, before
prescribing other increasingly invasive, expensive or less well tolerated
treatments.
Unfortunately, presently, only a limited number of treatment op-
tions have evidence of efficacy in patients who would meet the pro-
posed criteria for DTD. Table 3 lists treatment options set out in
guidelines for the treatment of MDD/unipolar depression (BAP
[Cleare et al., 2015], CANMAT [Kennedy et al., 2016; Milev et al.,
2016; Parikh et al., 2016], and WFSBP [Bauer et al., 2013]), with up-
dates to include treatment options that have become available since
publication of the guidelines, highlighting evidence for efficacy in pa-
tients with a history of treatment failure (based on various definitions of
treatment resistance). Our aim is not to make specific treatment re-
commendations, but rather to provide a comprehensive (though not
exhaustive) overview of potential treatment options and summarize the
available evidence to facilitate treatment decisions, to be tailored based
on patient, illness- and treatment-related factors as described above.
3.4.1.2 Treatment strategies. It is important to consider how the selected
treatment(s) will be used in relation to existing treatments (or in
relation to each other in the event of further treatment failure or
suboptimal response), i.e. augmenting existing treatments versus
switching to a new treatment approach. For patients with a partial
response (that is evidence of improvement in symptoms but short of a
substantial improvement or full remission – using a rating scale,
improvement in symptoms that is less than 50% improvement from
the baseline value) to their prior treatment, the consensus group
concurred that there is clearly a rationale for continuing that
treatment, assuming acceptable tolerability, and adding an adjunctive
treatment to enhance response. For patients with non-response to prior
treatment, there appears to be little difference in outcomes between
switch and augmentation strategies (Connolly and Thase, 2011).
Factors to consider, when contemplating treatment switching versus
augmentation, include how well the existing treatment is tolerated, risk
of withdrawal symptoms on discontinuation, and risk of drug-drug
interactions or non-compliance with a more complicated/burdensome
medication regimen if new treatment is added to existing treatment
(Kennedy et al., 2016; Nelson, 1998; Papakostas, 2009).
For patients with DTD who experience multiple pharmacological
treatment failures, it is important to recognize when to explore other
options, including neurostimulation. There may be little value in
prolonging trial-and-error of different pharmacological treatments,
especially those employing similar mechanisms of action; this may
simply delay potential treatment success with a different approach.
Neurostimulation is not reserved for patients only after all standard
pharmacological treatment options have been exhausted. Indeed, it is
not a stepwise progression from pharmacotherapy to neurostimulation;
pharmacological options may be revisited in case of failure of a non-
pharmacological approach. For example, esketamine or intravenous
ketamine may be considered before or after failure of ECT.
Furthermore, initiating neurostimulatory treatment does not mean
switching away from pharmacotherapy altogether. Antidepressant
maintenance therapy reduces relapse rates in patients undergoing ECT
(Cleare et al., 2015), and VNS is approved as an adjunctive treatment to
ongoing antidepressant treatment (Milev et al., 2016). Similarly, psy-
chotherapy may reduce relapse rates when added to medication, and
may work when drugs fail and vice versa (Schatzberg et al., 2005).
3.4.1.3 Measuring treatment success. When a new treatment strategy has
been initiated, its success may be judged largely from the patient's
perspective. However, a quantifiable outcome helps to gauge whether
treatment is producing measurable improvement and has been shown
to be associated with improved outcomes (Guo et al., 2015). Many
scales covering a range of domains are available (Baer and Blais, 2010).
Which exact scale is probably of little relevance – rather that scales are
used longitudinally to aid clinical decision making while managing the
patient's depression. The consensus group recommends the use of both
symptom rating scales (e.g., Patient Health Questionnaire [PHQ-9] or
Quick Inventory of Depressive Symptomatology [QIDS]) and measures
of psychosocial function (e.g., the Sheehan Disability Scale [SDS;
Sheehan and Sheehan, 2008] or the Functioning Assessment Short
Test [FAST; Rosa et al., 2007]). Alongside clinical assessment, the
patient's perspective is crucial to determine whether any improvement
in functionality is meaningful, and whether residual deficits have been
reduced to a manageable level. The patient therefore shares in the
decision making regarding next steps in the treatment pathway, and
what point to stop escalating treatment and accept the level of symptom
relief/functionality that has been achieved, considering their
preferences for what level of invasiveness or side effects they are
prepared to accept in pursuit of greater efficacy.
3.4.2. Target symptoms that are associated with poor outcomes
Symptoms such as anxiety and pain are associated with worse
outcomes in patients with depression (DeVeaugh-Geiss et al., 2010;
Fava et al., 2008). While there has been limited research exploring the
impact of targeting such symptoms, there was consensus among the
group that targeting them can potentially be a valuable strategy. This
might be utilizing antidepressant treatments that have demonstrable
efficacy for the associated symptoms (e.g., a SSRI for depression and
anxiety [Baldwin et al., 2006] or duloxetine for depression and pain
[Detke et al., 2002]). Alternatively, it may be utilizing treatments that
can specifically target the associated symptom (e.g., quetiapine or
pregabalin for anxiety [Bandelow et al., 2010; Montgomery et al.,
2006] or various analgesics for pain). Care needs to be exercised that
such treatments are not associated with a burden of adverse effects that
contribute to a worse quality of life or lead to iatrogenic problems.
3.4.3. Target symptoms to maximize function and quality of life
A key goal in the management of DTD is maximizing functional
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Table 3
Evidence-based treatment options for patients with non-response to first line treatments.
Treatment Use Evidence base in treatment-resistant patient populations*
Pharmacological
Aripriprazolea,b,c
Olanzapinea,b,c
Quetiapinea,b,c
Risperidonea,b,c
Adjunctive therapy - Meta-analyses (10–16 trials; N = 1500–3549 patients with TRD [various
definitions]) (Nelson and Papakostas, 2009; Papakostas et al., 2007; Spielmans et al.,
2013)
- Network meta-analysis (18 trials; N = 4422 patients with a current episode of MDD
and inadequate response to ≥1 course of conventional antidepressant therapy) found
that all agents listed, used at standard doses, showed superior efficacy to placebo,
when added to SSRIs/SNRIs (Zhou et al., 2015)
Brexpiprazolea Adjunctive therapy - Three Phase 3 RCTs in patients with inadequate response to 1–3 antidepressants
(n = 379–677; total N = 1559) (Hobart et al., 2018; Thase et al., 2015a, 2015b)
- One RCT in patients with inadequate response after 6 weeks’ antidepressant treatment
(Bauer et al., 2019); this trial did not meet the primary endpoint of increased rate of
full remission vs. placebo
Ziprasidonea Adjunctive therapy - One RCT in patients with MDD whose symptoms persisted after 8 weeks’ treatment
with escitalopram (n = 139; patients who had failed >3 antidepressant trials of
adequate dose and duration prior to enrolment were excluded) (Papakostas et al.,
2015)
Lithiuma,b,c Adjunctive therapy - Two meta-analyses (9–10 small trials; n = 7–62); lithium added to various
antidepressants including TCAs, second generation antidepressants, SSRIs,
tetracyclics, MAOIs (Bauer et al., 2010; Crossley and Bauer, 2007; Nelson et al.,
2014)
Thyroid hormones (tri-
iodothyronine)a,b,c
Adjunct to TCA
Adjunct to SSRI
- Meta-analysis (8 studies, including 4 RCTs; n = 292 patients with TRD)
(Aronson et al., 1996)
- Three small open-label studies (n = 11–25 [Abraham et al., 2006; Agid and
Lerer, 2003; Iosifescu et al., 2005]), one single-blind RCT (n = 142 [Nierenberg et al.,
2006]), one small double-blind RCT (n= 36 [Joffe et al., 2006]) (reviewed in Cooper-
Kazaz and Lerer, 2008)
S-adenosyl-L-methionine (SAMe)b Adjunctive therapy - One RCT (n = 73 patients with non-response to an SSRI at adequate dose and
duration) (Papakostas et al., 2010)
Esketamine (nasal spray) Adjunct to SSRI/SNRI - Two Phase 3 RCTs in patients with non-response to ≥2 antidepressants (total
N = 932) (Daly et al., 2019; Popova et al., 2019)
Ketamine (i.v. infusion)a,b Experimental;
monotherapy or adjunctive therapy
- Systematic review (25 studies including single- and multiple dose, open label studies
and double-blind RCTs; N = 399 patients with TRD [Serafini et al., 2014]) and
additional more recent studies (e.g., Fava et al., 2018; Phillips et al., 2019;
Singh et al., 2016 [n = 41–99]) generally support rapid antidepressant effects
- Meta-analysis (9 studies, including 5 specifically in treatment-resistant patients;
n = 15–73) supported efficacy of ketamine in treatment-resistant subgroup
(Fond et al., 2014)
- Data on long-term efficacy and safety are limited (Kennedy et al., 2016)
Ketamine (oral) Experimental;
adjunct to usual treatment
- One proof-of-concept RCT (n = 41 patients with TRD) (Domany et al., 2019)
- Case series (n = 22 patients with non-response to ≥3 adequate trials of
pharmacological treatments and ≥1 adequate trial of rTMS; open-label treatment);
modest efficacy reported (Al Shirawi et al., 2017)
- Systematic review (13 studies including patients with unipolar and bipolar depression)
(Rosenblat et al., 2019)
Pramipexolea Off-label; adjunctive therapy - One RCT (n = 60 patients with TRD [continued depression despite treatment with
≥1 prior antidepressant in the current depressive episode]) (Cusin et al., 2013)
- Case series (n = 42, including 24 with MDD and 18 with bipolar depression); patients
had failure of ≥4 adequate antidepressant trials (including non-response to ECT in 8
patients) (Fawcett et al., 2016)
Bupropriona,b,c
Buspironeb,c
Combination - One RCT (n = 565 patients with no remission after ~12 weeks citalopram
monotherapy) (Trivedi et al., 2006)
Modafinila,b Adjunctive therapy - Two RCTs (N = 348 patients with partial response to SSRIs, and persisting fatigue/
sleepiness) (Fava et al., 2007)
Tetracyclic medicationsb,c
(mirtazapine, mianserin)
Combination therapy (with SSRI or TCA) Rationale based on complementary MoAs; empirical data from RCTs specifically in TRD
populations are limited (Bauer et al., 2013; Cleare et al., 2015)
- Principle of combination therapy supported in general MDD population (e.g., RCT in
patients with MDD; n = 105 [Blier et al., 2010])
- RCT (n = 480 patients with TRD) did not find convincing evidence of a clinically
important benefit for mirtazapine in addition to a SSRI or a SNRI (Kessler et al., 2018
[MIR study])
MAOIsb,c Switch or combination with non-
serotonergic medications
Recognized in treatment guidelines as a possible approach following inadequate/non-
response to first-line treatment (Bauer et al., 2013; Cleare et al., 2015) although
empirical data from RCTs, particularly in TRD populations, is lacking
Psychotherapy
CBTa,b Adjunct to usual care - Open label RCT (n= 469 patients with TRD [BDI score≥14 after 6 weeks’ adequate
antidepressant treatment]) with CBT administered as adjunct to usual care
(Wiles et al., 2013)
CBASPa,c Adjunct to pharmacotherapy - Uncontrolled pilot study (n = 70 inpatients with chronic depression and history of
treatment resistance) (Brakemeier et al., 2015)
- Open-label RCT (n = 491 partial- or non-responders to pharmacotherapy)
(Kocsis et al., 2009)
- Augmentation of continued pharmacotherapy with CBASP did not produce
significantly different outcomes vs. optimized pharmacotherapy
(continued on next page)
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outcomes. Poorer function and quality of life have been shown to be
associated with poorer symptom control (IsHak et al., 2015); hence
optimizing symptom control as described above is important. However,
it is also important to assess which symptoms are identified by patients
as being associated with impairment in function and quality of life. A
frequently cited residual symptom is insomnia (Conradi et al., 2011).
Addressing this either pharmacologically using a hypnotic or sedative
medication (e.g. trazodone or mirtazapine), or psychotherapeutically
using, for example, cognitive behavioral therapy (CBT) for insomnia
(Cunningham and Shapiro, 2018), can lead to significant reductions in
distress caused by the symptoms as well as improvement in the de-
pression itself. Daytime fatigue and cognitive impairment are fre-
quently reported symptoms by patients with DTD (Conradi et al., 2011)
and these are associated with impairment in functioning (Fried and
Nesse, 2014). There are few evidence-based treatments to address these
problems (Salagre et al., 2017). However, some evidence supports the
use of modafinil augmentation for daytime fatigue (Goss et al., 2013)
and modafinil and vortioxetine for cognitive dysfunction (Kaser et al.,
2017; Mahableshwarkar et al., 2015; Vieta et al., 2018).
3.4.4. Manage comorbidities to reduce overall symptom burden
The importance of the identification of comorbidities of any type
has been emphasized above. There is little evidence to guide the
management of DTD in patients with comorbid disorders. However,
there was consensus around the principle that in such circumstances the
depression cannot be targeted alone, the comorbidity also needs to be
actively addressed. This may necessitate referral of the patient to an
appropriate specialist.
When considering comorbidities, the consensus group highlighted
the importance of assessing and addressing iatrogenic issues, such as
depression exacerbated by treatment utilized for a comorbid condition
(e.g., beta blockers or calcium channel antagonists for hypertension) or
drug-drug interactions either reducing the effectiveness of medications
targeting depression (e.g., concurrent administration with carbamaze-
pine) or leading to problematic adverse effects (e.g., the combination of
an SSRI for depression and amitriptyline used for pain control).
3.4.5. Optimize long term outcomes by ensuring adequate prophylaxis
Depression is a highly recurrent condition. Many patients with DTD
Table 3 (continued)
Treatment Use Evidence base in treatment-resistant patient populations*
Neurostimulation
rTMSa,b Usually used as adjunct to pharmacotherapy - >30 systematic reviews and meta-analyses; most studies involved patients who with
≥1 or ≥2 failed antidepressant trials (Milev et al., 2016)
- Meta-analysis of studies specifically in patients with TRD defined as≥2 antidepressant
treatment failures (18 studies using rTMS in augmentation or switch settings;
n = 12–74) (Gaynes et al., 2014)
- Meta-analysis of studies comparing rTMS vs sham (23 studies) or ECT (6 studies)
(n=~15–300; various definitions for TRD) (Health Quality Ontario, 2016)
- Statistically significant but small effect size vs. sham (smaller than pre-specified
clinically important treatment effect); ECT superior to rTMS in active comparator
studies
ECTab,c, Most effective when used in combination
with pharmacotherapy
- Meta-analysis (7 studies; N = 585 patients with previous pharmacotherapy failure)
(Heijnen et al., 2010)
- ECT was effective in TRD patients, although response rate was lower than that for
patients without a history of pharmacotherapy failure (48% vs. 65%)
tDCSa Efficacy enhanced when used in combination
with pharmacotherapy or psychotherapy
- Four meta-analyses (6–10 trials; N = 200–393 patients) (Berlim et al., 2013;
Brunoni et al., 2016; Meron et al., 2015; Shiozawa et al., 2014)
- Three meta-analyses found modest superiority over sham with small effect sizes
(Brunoni et al., 2016; Meron et al., 2015; Shiozawa et al., 2014), one found no
superiority over sham (Berlim et al., 2013)
- History of treatment resistance was associated with poorer response to tDCS
(Brunoni et al., 2016; Meron et al., 2015)
VNSa,b,c Adjunct to usual treatment - RCT (n = 235 patients with 2–6 treatment failures) (Rush et al., 2005a, 2005b)
- Open-label follow up (12 months) suggested growing long-term benefit
- Open, uncontrolled study (n = 74 patients with TRD) (Bajbouj et al., 2010;
Schlaepfer et al., 2008)
- Outcomes reported at 3, 12 and 24 months, showing increasing efficacy over time
- Meta-analysis (6 studies [including the studies described above]; n = 60–636)
supports overall benefits of VNS (adjunct to usual treatment) over usual treatment
alone (Berry et al., 2013)
- 5-year observational study (n = 795 patients with ≥4 failed treatments [including
ECT in approximately 50% of patients]) showed adjunctive VNS enhanced
antidepressant effects compared with treatment as usual in a severely ill patient
population (Aaronson et al., 2017)
DBSa,b Experimental - Two meta-analysis (9–14 small studies; N ≥ 190) (Kisely et al., 2018; Zhou et al.,
2018)
MSTa Experimental - Two RCTs (n = 20–37 patients with TRD) (Fitzgerald et al., 2018; Kayser et al.,
2011)
- Both studies showed equivalent efficacy of MST to ECT
The list of options included in this table was arrived at via review of the options set out in guidelines for MDD/unipolar depression (CANMAT, BAP, WSFBP), and
selecting those with evidence in patient populations with TRD (based primarily on literature cited in the guidelines). Related literature published since the guidelines,
and new treatment options that have become available since guidelines were published (2016), e.g. esketamine, have been added.
Treatments listed in: aCANMAT guidelines; bBAP guidelines; cWFSBP guidelines; *Definitions for TRD/degree of treatment resistance noted where available
BAP, British Association of Psychopharmacology; CANMAT, Canadian Network for Mood and Anxiety Treatments; CBASP, cognitive behavioral analysis system of
psychotherapy; CBT, cognitive behavioral therapy; DBS, deep brain stimulation; ECT, electroconvulsive therapy; i.v., intravenous; MAOI; monoamine oxidase
inhibitor; MDD, major depressive disorder; MST, magnetic seizure therapy; n, number of patients in trial; N, total number of patients in pooled trials/meta-analysis;
RCT, randomized controlled trial; rTMS, repetitive transcranial magnetic stimulation; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI, selective ser-
otonin reuptake inhibitor; TCA, tricyclic antidepressant; tDCS, transcranial direct current stimulation; TRD, treatment-resistant depression; VNS, vagus nerve sti-
mulation; WFSBP, World Federation of Societies of Biological Psychiatry.
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have a waxing and waning course to their depressions. The harder it is
to treat in the acutely, the higher the risk of relapse (Rush et al., 2006).
Adequate prophylaxis is important to minimize the likelihood of and
severity of symptom exacerbations as well as full-blown relapses for
patients who have made a full or partial response to treatment. The
burden of adverse effects of ongoing treatment, and importance of
maintaining adequate dosing, needs to be addressed in shared decision
making around long term treatment. Patients should be counselled that
discontinuation of treatment may well be associated with a relapse of
illness and hence in such circumstances there needs to be careful
monitoring of adherence. It is also important to consider the time scale
of effects and response to neurostimulatory treatment. For example,
ECT can be highly effective acutely in patients who have not responded
to a number of medications (Heijnen et al., 2010), but has a high re-
lapse rate in the months after an acute course (Itagaki et al., 2017;
Jelovac et al., 2013). Conversely, antidepressant effects of VNS can take
around 6 months to become evident and two years or more to plateau
(Aaronson et al., 2017; Berry et al., 2013), but durable responses have
been reported (Kumar et al., 2019). It should be noted that rates and
duration of response to VNS and ECT have not been compared directly.
The effectiveness and durability of any medication, psychosocial
therapy or neurostimulatory treatment is likely to be enhanced by a
patient reducing their use of recreational drugs and alcohol and
learning to manage stressors. The success of longer-term treatments
depends substantially on active patient engagement and collaboration
in their own treatment, as described below.
3.4.6. Use self-management techniques to empower patients
Hopelessness can lead patients to not only feel that treatment al-
ternatives are unlikely to work and there is no chance that they will
ever feel better, but also to feel powerless to do anything about the
depression themselves. Encouraging self-management strategies can be
very empowering for many patients. There are potentially many ele-
ments to this and these need to be tailored to the individual patient
(Rush and Thase, 2018). Perhaps most importantly, as described by
Rush et al. (2019), is encouraging scepticism of the pervasive hope-
lessness that patients feel. In addition, encouraging a healthy lifestyle
through good diet and sleep habits and exercise can be helpful; the
latter have significant antidepressant effects (Morres et al., 2019). Be-
havioral activation, with activity scheduling and supporting active
community reconnection possibly by utilising "social prescribing", can
be beneficial for many patients alongside psychological, pharmacolo-
gical and neurostimulatory treatments, especially for patients unable to
engage with more formal psychotherapies. Similarly, enhancing a pa-
tient's ability to cope with residual depressive symptoms and making
occupational or interpersonal changes to allow them to function as
optimally as possible within their capacities, can be vital for patients
with DTD of any chronicity. An additional self-management option is
the burgeoning number of on-line resources to manage depression,
anxiety and sleep problems. Some patients also find great benefit in
using on-line symptom rating tools to monitor their progress.
3.4.7. Use integrated mental health services to help provide a sense of
containment and ensure wide consideration of treatment options
A key principle in the management of DTD is shared decision
making as described above. However, this is only part of a patient-
centred approach, which ideally includes having care pathways that are
responsive to the needs of the patient. The consensus group recognizes
that this is not always the reality in many healthcare systems.
Nevertheless, it was felt important to emphasize the importance for
patients with DTD to have easy access into primary and secondary care,
with clear guidance as to when and how to achieve this. DTD is asso-
ciated with a vast economic burden to health care systems and wider
society. It is likely that improved access to care would decrease this
burden and prove to be cost effective. It also helps provide a sense of
containment to the patient.
Taking a patient-centred approach also entails considering the pa-
tient's partner, family and/or other significant individuals in their life.
Living with, and supporting, a patient with DTD can place a great strain
on a carer; such individuals need support in their own right.
Additionally, close family and friends can be excellent therapeutic allies
or saboteurs; it is well worth clinicians trying to ensure they are the
former rather than the latter (with the consent of the patient).
Finally, an important principle in the management of DTD is not to
give up on finding a treatment strategy that will work for the patient;
this could instil feelings of hopelessness in the patient, which is a risk
for suicidality. If the treating physician reaches a point where it is not
clear what approach to try next, we advocate seeking a second opinion,
or consulting a colleague who may have clinical experience with dif-
ferent options (e.g., a physician who has not used neuromodulation
themselves may wish to refer a patient to a specialist who has experi-
ence in that area).
3.4.8. Establish regular review of the patient's diagnosis and treatment
Following an initial detailed assessment, regular re-assessment is a
critical part of long-term patient care. The consensus group re-
commends that, in addition to routine clinical reviews, patients with
DTD should have a formal case review/overview conducted at least
annually. The diagnosis of the patient should be reviewed, and the
patient should be screened for comorbidities. Central to an annual
formal review is assessing symptom control, level of functioning and
quality of life using rating scales.
At the review a range of questions should be considered:
• Has there been a meaningful improvement regarding clinical
symptoms, cognition or psychosocial functioning, constituting a
successful treatment response in relation to the patient's own
treatment goals?
• Have there been new episodes of depression since the last review,
and if so, can precipitating factors/triggers, including possibly
medication changes, be identified?
• Are there any new/current psychosocial stressors that need to be
addressed?
• Has there been adherence to treatment and how has this been tol-
erated?
• How well is the patient engaging in behavioral activation?
• Is there an opportunity to ‘clean up’ medication and eliminate ir-
rational polypharmacy – discontinuing medications that are not
producing positive effects, or medications with redundancy between
modes of action?
• Is switch or augmentation of current medication warranted, if re-
sponse is sub-optimal?
• Are all options being considered (beyond pharmacotherapy)?
• Have any new treatments become available, and are they worth
considering for this patient?
• Is a second opinion or referral warranted (e.g., to a centre that offers
interventions that are not universally available, such as VNS)?
There should be a clear decision as to the direction of treatment.
Any residual symptoms should be addressed where possible.
Therapeutic drug monitoring may be useful, if available, to confirm that
all medications are reaching therapeutic doses adequate for target en-
gagement. The group do not recommend making unnecessary changes
to a treatment that is producing benefits. Dosing should be maintained;
whatever dose was needed to achieve acute improvement is the dose
needed to maintain the improvement, at least for SSRIs (Fava et al.,
1995; Franchini et al., 1998). If a patient is responding to a branded
medication, it is recommended continuing that specific product rather
than switching to a generic equivalent, as such a switch can be asso-
ciated with a range of issues including reductions in efficacy, reduced
medication adherence and increased health care cost (Blier et al.,
2019). Similarly, if a generic product is working, it is preferable to
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continue with the same one. In contrast, if a patient has not responded
to a generic drug, a switch to the branded medication may be worth-
while, especially if further investigation is necessary before selecting
the next therapeutic step. Consideration should be given to whether all
avenues have been explored regarding prophylaxis and mitigation of
exacerbations of symptoms. This might include a review of personalized
relapse signatures, resilience training and stress management, and in-
creasing protective factors and reducing risk factors (Rush and
Thase, 2018).
4. Limitations
This consensus document is not based on a formal process, such as
using the Delphi technique. The reasons for this are that at the initial
meeting of the authors a very broad range of questions were considered
for which there was a strong consensus such that a Delphi process was
not felt to be warranted. During the iterative process of producing the
manuscript little disagreement between authors was identified. Where
there was a lack of consensus, this is stated. Otherwise, the iterative
process of producing the manuscript was considered complete when all
contributors were happy to be identified as authors.
A potential limitation of this consensus in clinical practice is that the
recommendations are based on a view of best practice. The health care
environment in which an individual clinician may significantly limit
what is possible.
5. Conclusions
An inclusive definition of DTD as “depression that continues to
cause significant burden despite usual treatment efforts” is proposed,
along with principles for the management of DTD. The broad per-
spective encompassed by DTD has advantages over applying the label
‘treatment resistant’ and focussing on next steps on the treatment
pathway, providing greater scope for addressing other factors that
could influence outcomes. Recommended key principles in the man-
agement of DTD including a thorough assessment, both initially after
identifying a patient as having suspected DTD and at regular intervals
during long-term follow up; the use of a three-dimensional framework
to facilitate identification of barriers to successful treatment; a patient-
centred approach based on shared decision making around all aspects
of treatment; and optimizing medication choices and doses for each
person as well as selecting and implementing specific psychosocial in-
terventions in order to achieve optimal symptom control, while re-
cognizing that full resolution of symptoms may not be achievable for
the individual patient. DTD may provide a more clinically useful con-
ceptualization of patients with TRD as it implies a search for the ob-
stacles that prevent the achievement of a sustained symptom free state
with a return to premorbid function. When that ideal goal is not met,
the goal of the intervention changes to optimizing symptom control,
function and quality of life over the longer term.
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